Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Equity Income: 2022-2024

Historic Equity Income for Amphastar Pharmaceuticals (AMPH) over the last 2 years, with Mar 2024 value amounting to -$573,000.

  • Amphastar Pharmaceuticals' Equity Income rose 27.01% to -$573,000 in Q1 2024 from the same period last year, while for Mar 2024 it was -$1.8 million, marking a year-over-year decrease of 40.51%. This contributed to the annual value of -$573,000 for FY2024, which is 71.08% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Equity Income stood at -$573,000 for Q1 2024, which was down 13.47% from -$505,000 recorded in Q4 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Equity Income peaked at -$57,000 during Q4 2022, and registered a low of -$785,000 during Q1 2023.
  • For the 3-year period, Amphastar Pharmaceuticals' Equity Income averaged around -$414,556, with its median value being -$390,000 (2023).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Equity Income tumbled by 785.96% in 2023 and then climbed by 27.01% in 2024.
  • Over the past 3 years, Amphastar Pharmaceuticals' Equity Income (Quarterly) stood at -$57,000 in 2022, then plummeted by 785.96% to -$505,000 in 2023, then rose by 27.01% to -$573,000 in 2024.
  • Its Equity Income was -$573,000 in Q1 2024, compared to -$505,000 in Q4 2023 and -$390,000 in Q3 2023.